rs1057519824, MET

N. diseases: 10
Source: ALL
Disease Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
Neoplasms
CUI: C0027651
Disease: Neoplasms
0.710 GeneticVariation CLINVAR An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. 17483355 2007
Neoplasms
CUI: C0027651
Disease: Neoplasms
0.710 GeneticVariation BEFREE By this approach, Met Y1253D was detected in tumours of 15 out of 13</span>8 patients (10.9%). 14627992 2003
Carcinoma
CUI: C0007097
Disease: Carcinoma
0.700 GeneticVariation CLINVAR Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. 12460923 2002
Neoplasm Metastasis
CUI: C0027627
Disease: Neoplasm Metastasis
0.020 GeneticVariation BEFREE Distant metastasis-free survival (P = 0.008) was associated with MET Y1253D. 19639388 2009
Neoplasm Metastasis
CUI: C0027627
Disease: Neoplasm Metastasis
0.020 GeneticVariation BEFREE The Y1235D mutation identified in metastases was shown to induce constitutive activation and a motile-invasive phenotype on transduced carcinoma cells. 16245927 2005
Squamous cell carcinoma of the head and neck
0.010 GeneticVariation BEFREE The observed association between MET Y1253D-activating point mutation and decreased distant metastasis-free survival in advanced HNSCC suggests that MET may be a potential target for specific treatment interventions. 19639388 2009
Secondary Neoplasm
CUI: C2939419
Disease: Secondary Neoplasm
0.010 GeneticVariation BEFREE The Y1235D mutation identified in metastases was shown to induce constitutive activation and a motile-invasive phenotype on transduced carcinoma cells. 16245927 2005
Oropharyngeal Carcinoma
CUI: C2349952
Disease: Oropharyngeal Carcinoma
0.010 GeneticVariation BEFREE Our results provide evidence that the Met-activating mutation Y1253D is present in a notable subset of patients with oropharyngeal cancer and indicate that it may interfere with radioresponsiveness of these tumours, supporting the notion of aberrant Met signalling as a potential target for radiosensitization. 14627992 2003
Malignant Squamous Cell Neoplasm
CUI: C0751688
Disease: Malignant Squamous Cell Neoplasm
0.010 GeneticVariation BEFREE We determined the prevalence and clinical impact of the Met-activating mutation Y1253D in patients with squamous cell cancer of the oropharynx treated by radical radiotherapy. 14627992 2003
Malignant neoplasm of oropharynx
CUI: C0153382
Disease: Malignant neoplasm of oropharynx
0.010 GeneticVariation BEFREE Our results provide evidence that the Met-activating mutation Y1253D is present in a notable subset of patients with oropharyngeal cancer and indicate that it may interfere with radioresponsiveness of these tumours, supporting the notion of aberrant Met signalling as a potential target for radiosensitization. 14627992 2003
Oropharynx (excludes nasopharynx)
CUI: C0549523
Disease: Oropharynx (excludes nasopharynx)
0.010 GeneticVariation BEFREE We determined the prevalence and clinical impact of the Met-activating mutation Y1253D in patients with squamous cell cancer of the oropharynx treated by radical radiotherapy. 14627992 2003
Squamous cell carcinoma
CUI: C0007137
Disease: Squamous cell carcinoma
0.010 GeneticVariation BEFREE We determined the prevalence and clinical impact of the Met-activating mutation Y1253D in patients with squamous cell cancer of the oropharynx treated by radical radiotherapy. 14627992 2003